Browse the evidence

Lateral hypothalamic area (LHA) neurons coordinate energy balance by integrating peripheral nutrient cues with ingestive, locomotor, and arousal behaviors.

Understanding how the brain coordinates hunger, activity, and sleep is key to managing weight. The LHA plays a central role in this process, suggesting that treatments for obesity or eating disorders might target specific neuronal populations within this area.

Melanin-concentrating hormone (MCH) neurons in the LHA promote feeding and general intake behavior, while their blockade can increase energy expenditure and promote weight loss.

Research into MCH receptors shows potential for treating obesity by reducing food intake and increasing energy expenditure. However, current treatments are not yet available for humans, and lifestyle changes remain the primary strategy.

Orexin (OX) neurons in the LHA promote feeding, arousal, and physical activity, and their disruption is linked to sleep disorders like narcolepsy.

Orexin neurons are critical for both wakefulness and energy balance. Disruptions in this system can lead to sleep disorders and metabolic issues. Current treatments for narcolepsy target OX receptors, highlighting their importance.

Lower skeletal muscle lipoprotein lipase (SMLPL) activity is associated with a higher 24-hour respiratory quotient (RQ), indicating a lower ratio of fat oxidation to carbohydrate oxidation, which predisposes individuals to obesity.

Your body's tendency to store fat versus burn it is partly determined by the activity of an enzyme in your muscles called lipoprotein lipase (LPL). Lower levels of this enzyme mean your body oxidizes less fat and more carbohydrates, which is a known predictor of future weight gain. While you cannot directly 'dose' this enzyme, understanding that muscle metabolism plays a critical role in fat partitioning highlights why some individuals gain weight more easily than others despite similar caloric intakes.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with increased subclinical atherosclerosis (measured by carotid intima-media thickness and coronary artery calcification) and incident cardiovascular events, but does not independently increase cardiovascular mortality risk after adjusting for confounders.

If you have MASLD, prioritize cardiovascular risk management (blood pressure, lipids, glucose) as aggressively as you manage your liver health. Your risk of heart events is elevated, but your risk of dying from liver failure is lower than dying from heart disease. Comprehensive cardiometabolic risk management is warranted.

Enhanced Negative Work-based Training (ENT) does not significantly improve linear sprinting ability (10m and 30m) in semi-professional soccer players during the in-season period.

Do not rely on a single weekly flywheel session to improve your straight-line speed during the season. While it helps with change of direction and injury prevention, it does not significantly impact 10m or 30m sprint times in semi-professional players. Focus on specific speed training for linear sprinting.

During short-term concurrent training (8 weeks), combining resistance training with either high-intensity interval training (HIT) or work-matched moderate-intensity continuous training (MICT) attenuates maximal lower-body strength gains to a similar degree compared to resistance training alone, indicating that endurance training intensity is not a critical mediator of the interference effect.

If you are doing both cardio and weights, don't worry about choosing 'easy' cardio to protect your strength. As long as you burn the same amount of energy (work-matched), high-intensity intervals will interfere with your strength gains just as much as moderate steady-state cardio. Focus on managing your total volume and recovery rather than avoiding high intensity.

Earlier age at menarche (specifically onset before 11 years) is associated with a significantly higher risk of developing type 2 diabetes and elevated cardiometabolic risk factors in adult women, independent of early-adulthood BMI.

For women who experienced early puberty (before age 11), there is a statistically higher baseline risk for type 2 diabetes and metabolic issues later in life, independent of their current weight. This does not mean diabetes is inevitable, but it suggests that metabolic monitoring (e.g., checking HbA1c, fasting glucose, and lipids) should be prioritized earlier and more frequently than for those with later menarche, starting in early adulthood.

Financial sponsorship by food and beverage companies in nutrition research and professional activities systematically biases outcomes to favor the sponsor's commercial interests, creating a conflict of interest that compromises the credibility of dietary advice.

When evaluating nutrition advice, check who funded the research or the organization providing the guideline. If a food company sponsored the study or the professional society, treat the conclusions with skepticism, especially if they align with the sponsor's product sales. Disclosure alone is not a guarantee of unbiased science.

High baseline and post-intervention levels of circulating microRNA-935 (c-miR-935) are associated with low weight loss response (<5% body mass loss) to a combined diet and exercise intervention, whereas high responders (>10% loss) exhibit lower levels.

If you are following a structured diet and exercise plan and seeing very little weight loss despite good adherence, your body's molecular response (specifically c-miR-935 levels) might be blunting your results. This doesn't mean the plan is wrong for you, but it may need adjustment. Consult a professional to see if biomarker testing or protocol modification (e.g., increasing the energy deficit or changing exercise type) is warranted.

Increases in circulating microRNA-221 (c-miR-221) and microRNA-223 (c-miR-223) abundance occur in both high and low responders to a combined diet and exercise intervention, suggesting these changes are driven by the exercise stimulus rather than the magnitude of weight loss.

Consistent exercise leads to beneficial molecular changes (increased c-miR-221 and -223) regardless of how much weight you lose. These changes are linked to improved energy metabolism and exercise adaptation. Focus on the consistency of the exercise stimulus for these health benefits, even if weight loss is slower than expected.

In individuals with incident type 2 diabetes, higher pre-diagnosis BMI is positively associated with an increased risk of microvascular complications (kidney disease and neuropathy), but not macrovascular complications.

For someone with newly diagnosed Type 2 Diabetes, maintaining a healthy pre-diagnosis BMI is crucial for preventing kidney and nerve damage. While weight loss after diagnosis shows benefits, the baseline weight status before diagnosis significantly impacts long-term microvascular risk. Focus on preventing weight gain and managing metabolic health markers.

GLP-1 receptor agonists do not significantly increase energy expenditure in humans, despite evidence in animal models.

Don't expect GLP-1 drugs to burn extra calories at rest. They work by reducing food intake.

L-cells are not a homogeneous population; they are anatomically heterogeneous, with proximal (duodenal/jejunal) L-cells primarily secreting GLP-1 in response to macronutrients, while distal (ileal/colonic) L-cells co-secrete PYY and respond to microbial metabolites like SCFAs and bile acids.

Your gut's hormonal response to food depends on where the food is absorbed. Eating fiber and fats that reach the lower intestine (via fermentation or specific fats) stimulates different hormones (like PYY) than eating simple sugars in the upper intestine. A diverse diet that reaches different parts of the gut may optimize this hormonal signaling better than focusing on a single nutrient type.

Higher circulating concentrations of fatty acids produced via de novo lipogenesis (specifically 16:0, 16:1n7, and 18:0) are positively associated with an increased incidence of type 2 diabetes.

High levels of certain fats produced by your body (de novo lipogenesis) from carbs and alcohol are linked to a higher risk of type 2 diabetes. This suggests that managing carbohydrate and alcohol intake may help regulate these specific internal fat pathways, potentially lowering diabetes risk, independent of overall body weight.

The association between oleic acid (18:1n9) and type 2 diabetes risk is attenuated to non-significance when adjusted for triglycerides and palmitic acid (16:0), suggesting its risk is dependent on overall de novo lipogenesis activity rather than being an independent driver.

While high levels of some fats made by your body are linked to diabetes, the link for oleic acid (found in olive oil) disappears when you account for overall metabolic health markers like triglycerides. This implies that focusing on the broader metabolic context (carb/alcohol intake) is more important than demonizing specific fats like oleic acid.

Deletion or inhibition of MKK6 in white adipose tissue increases energy expenditure and protects against diet-induced obesity and diabetes by enhancing thyroid hormone (T3)-mediated browning of white fat.

This research suggests that blocking MKK6 in fat tissue could help treat obesity by making fat burn more energy, similar to brown fat. While not a current human treatment, it highlights thyroid hormone sensitivity and fat metabolism as key targets for future obesity drugs.

Using a single muscle biopsy with a long tracer incorporation time (approx. 3 hours) yields reliable myofibrillar protein synthesis rates comparable to the traditional two-biopsy method.

If you are measuring muscle protein synthesis using stable isotopes, you can safely use a single muscle biopsy instead of two, provided you extend the tracer incorporation time to approximately 3 hours. This reduces subject discomfort and risk without compromising the reliability of the results, as long as you use plasma protein for baseline enrichment.

Enriching a bolus protein drink with a small amount of crystalline tracer (4% enrichment) does not disrupt isotopic steady-state conditions in plasma or intracellular precursor pools.

For researchers using stable isotopes to measure muscle protein synthesis, you can enrich your protein drink with a small amount of tracer (e.g., 4% enrichment) without disrupting the steady-state conditions in your precursor pools. This allows for accurate measurement of muscle protein synthesis after a bolus protein feeding, even following exercise.

Enteroendocrine cells (EECs) regulate the gut-brain axis through two distinct mechanisms: slow endocrine hormone release into the bloodstream and rapid synaptic signaling via neuropod cells.

Your gut has a direct 'phone line' to your brain. Foods trigger specific cells (EECs) that send signals either slowly through hormones or instantly through nerves. This is why drugs like semaglutide (Ozempic) work—they amplify these natural signals to regulate hunger and blood sugar. Understanding this helps explain why gut health directly impacts mood and metabolism.

Neuropod cells communicate nutrient information to the vagus nerve primarily via glutamate release, allowing for rapid distinction between sugar and artificial sweeteners.

Your gut has a specific 'sugar detector' (neuropod cells) that sends a fast signal to your brain using glutamate. This signal is triggered by real sugar (sucrose) but not by artificial sweeteners. This might explain why artificial sweeteners don't always satisfy sugar cravings or trigger the same metabolic responses as real sugar.

Serotonin (5-HT) released from enterochromaffin (EC) cells modulates visceral sensitivity and pain signaling via direct synaptic interaction with nociceptive neurons.

If you have IBS or chronic gut pain, your gut cells (EC cells) might be sending too many pain signals to your brain using serotonin. Blocking these signals (with specific antagonists) can reduce pain and anxiety, showing that gut pain is a neurological issue, not just inflammation.

Standard anti-diabetic treatments often fail to achieve recommended cardiometabolic targets (HbA1c, BP, LDL) in real-world clinical settings, leaving most patients with uncontrolled risk factors.

If you are taking medication for diabetes, do not assume your health is fully managed. This study found that less than 25% of treated patients achieved optimal levels for blood sugar, blood pressure, and cholesterol. You must actively manage your weight and lifestyle alongside your medication to truly control your risk.

Genetically lower serum adiponectin levels cause increased insulin resistance, as evidenced by Mendelian randomization analysis of the ADIPOQ rs266729 polymorphism.

This study provides genetic evidence that low levels of the hormone adiponectin contribute directly to insulin resistance. While you cannot directly 'dose' adiponectin like a drug, this highlights the importance of lifestyle factors known to support healthy adiponectin levels, such as maintaining a healthy body weight and engaging in regular physical activity, as these may help mitigate insulin resistance through this hormonal pathway.